Zolidina

Quick links to important sections

Zolidina

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zolidina

Property Description
Active ingredient Cefazolin Sodium
Form Powder for Injection (Parenteral Solution)
Pharmacological class First-Generation Cephalosporin Antibiotic
Common use Fighting bacterial infections; Surgical prophylaxis
Origin Semi-synthetic

What Type of Antibiotic is Zolidina?

Zolidina is an anti-infective drug whose active substance is the generic compound Cefazolin Sodium, belonging to the family of beta-lactam antibiotics. It is formally classified as a first-generation cephalosporin, which denotes its foundational position within this broad pharmacological class. Cefazolin itself is a semi-synthetic derivative, meaning its structure is based on a natural compound but chemically modified for enhanced efficacy and stability.

This classification is clinically recognized for its strong activity against a wide range of common Gram-positive bacteria, which are frequently implicated in infections of the skin and soft tissues. This feature represents a key differentiating factor of first-generation cephalosporins when compared to later generations that prioritize Gram-negative coverage. Other compounds with this exact formulation include brands such as Kefzol and Ancef.

Composition and Physical Form of Cefazolin

The medication is formulated as a sterile, single-ingredient product of Cefazolin Sodium, typically supplied as a powder for injection. The powder must be professionally reconstituted, or mixed with a suitable parenteral solution before use. The need for this specialized preparation is a distinguishing feature from oral antibiotics.

The resulting liquid preparation must be delivered via parenteral administration, usually by the intravenous (IV) or intramuscular (IM) route. Cefazolin attains reliably high serum levels necessary for treating systemic bacterial threats. The compound is suitable for acute clinical use.

Cefazolin's General Therapeutic Purpose

The overall therapeutic purpose of Cefazolin is the elimination of susceptible bacterial pathogens responsible for infection. The drug achieves this through a direct, potent bactericidal action by interfering with the bacteria's ability to construct a stable outer cell wall. By blocking this essential synthesis process, Cefazolin causes the bacterial cell to break down. This specific, targeted function makes the compound a widely used agent both for treating existing bacterial diseases and for prophylaxis—preventing infection—in the context of many surgical procedures.

What side effects are possible with Zolidina?

Possible side effects and safety information

Adverse reactions associated with Zolidina (Cefazolin) are classified by regulatory authorities based on the physiological systems they affect and their documented frequency. The official safety profile details both common effects and specific serious adverse reactions.

Adverse Reaction Scope and Classification

The most common adverse reactions documented in official labeling affect the Gastrointestinal System, including nausea, vomiting, and diarrhea, as well as Immune System Disorders (allergic reactions). Other reported reactions include pain at the injection site and temporary elevations in liver enzymes (Hepatobiliary Disorders).

Category Documented Adverse Reactions (Examples)
Gastrointestinal Disorders Diarrhea, Nausea, Vomiting, Pseudomembranous colitis
Immune System/Skin Anaphylaxis, Skin rash, Urticaria, Severe skin reactions (e.g., SJS)
Blood & Lymphatic System Leukopenia, Neutropenia, Thrombocytopenia (rare)
Nervous System Seizures, Dizziness

Serious Adverse Reactions and Safety Constraints

Serious adverse reactions explicitly noted in regulatory documents include Anaphylaxis, which can be severe, and Clostridioides difficile-associated Diarrhea (CDAD), which may range up to fatal colitis. CDAD may manifest up to two months after treatment has concluded.

Cefazolin is contraindicated in patients with a history of immediate hypersensitivity reactions to cefazolin, cephalosporins, penicillins, or other beta-lactam antibacterial drugs, due to documented cross-hypersensitivity potential. For patients with renal impairment, a specific safety note highlights the increased risk of Seizures and CNS toxicity if dosage adjustments are not made according to the label's guidelines. Prolonged use may also lead to the overgrowth of nonsusceptible microorganisms (superinfection).

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Zolidina (Cefazolin Sodium) focuses on the risk of central nervous system (CNS) toxicity in cases of over-exposure.

Documented Overdose Presentations

High concentrations of the drug, particularly when accumulation is likely, are officially documented to be associated with seizures. Other signs reported following the administration of inappropriately large doses of parenteral cephalosporins may include dizziness, paresthesia (tingling/numbness), headache, and gastrointestinal distress.

Severe outcomes such as Status Epilepticus (prolonged or recurrent seizures) and signs of severe CNS toxicity are the primary life-threatening concerns cited in regulatory materials.

Population-Specific Note: The risk of seizures and neurotoxicity is explicitly heightened in patients with renal impairment (kidney failure) due to the impaired clearance of the drug.

Emergency-Response Statements

In case of suspected overdosage, the official labeling mandates that medical attention be sought immediately.

Required Immediate Action Label-Derived Phrasing
Urgent Medical Contact Contact a Poison Control Center or Emergency Room at once
Call Emergency Services Call 911 if the victim has collapsed, had a seizure, is experiencing trouble breathing, or cannot be awakened

Supportive Measures and Antidote

Management of overdosage consists of symptomatic and supportive treatment. The medication should be promptly discontinued, and anticonvulsant therapy may be administered if clinically indicated to manage seizures. Regulatory documents do not specify a known antidote. Monitoring of vital signs, blood gases, and serum electrolytes is required, and hemodialysis may be considered for removal of the drug, especially in patients with compromised kidney function.

Therapeutic Uses of Zolidina

Main Uses and Benefits of Zolidina (Cefazolin)

Zolidina (Cefazolin) is commonly used both in managing existing infections and for prevention during certain surgical procedures. The medication is indicated for conditions characterized by periods of heightened symptoms and increased physiological stress.

The medication is used for managing severe bacterial infections, including those affecting the bloodstream (septicemia), bones and joints (osteomyelitis), and soft tissues (cellulitis). It is applied in clinical settings that involve acute or unstable symptom patterns, helping to address symptom clusters that may become intense or disruptive, such as high fever, chills, swelling, and pain related to the infectious process.

Prophylaxis in High-Risk Surgery

The medication is also applied as perioperative prophylaxis (prevention), used for surgical candidates undergoing major procedures like cardiac or orthopedic surgery, to manage the risk associated with developing a post-operative infection. This use provides supportive relief when symptoms interfere with routine activities.

“It is commonly used across conditions presenting with acute episodes, providing support that helps ease the overall symptom burden.”


Quick Fact: Relief for Acute Localized and Systemic Symptoms Cefazolin is used for managing symptoms related to systemic imbalance (fever/chills) and inflammatory states (swelling/pain) across various severe infections, supporting general well-being during symptomatic phases.

Eligibility and Restrictions for Use

Eligibility and Contraindications for Zolidina (Cefazolin)

The population eligibility for Zolidina is strictly defined by regulatory documents, outlining who is permitted, restricted, or prohibited from using the medicine.

Absolute Contraindications

Zolidina is contraindicated and must not be used by patients with a known history of immediate hypersensitivity (severe allergic reaction) to Cefazolin or to any other drug in the cephalosporin class. Use is also prohibited for individuals with a history of immediate hypersensitivity to penicillins or other beta-lactam antibiotics due to the risk of cross-allergenicity.

Age and Organ Function Restrictions

Population Group Eligibility Status Key Restriction/Consideration
Adults & Older Adults Approved Use Older adults require renal function assessment due to the higher likelihood of decreased kidney function.
Pediatrics Approved Use (ge 1 month) Safety and effectiveness are not established for infants less than 1 month of age.
Renal Impairment Conditional Use Use requires a mandatory reduction in daily dosage to prevent accumulation and potential adverse effects.
Pregnancy Conditional Use (Category B) Use is permitted only if clearly needed, as adequate human studies are lacking.
Lactation Conditional Use/Caution Cefazolin is present in low concentrations in human milk, and caution is advised when administering to nursing women.

Eligibility is also restricted for patients with a history of colitis or other severe gastrointestinal disease, requiring caution due to the risk of associated diarrhea.

What should I know about interactions with other medicines?

Zolidina (linezolid) is classified as a reversible, non-selective monoamine oxidase inhibitor (MAOI), which dictates its most significant interaction constraints according to regulatory documents.

Contraindicated Combinations

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is strictly forbidden. This restriction extends to administering Zolidina within two weeks of stopping any MAOI. This rule is in place to prevent the risk of a severe reaction.

Pharmacodynamic Interactions

Caution is required when Zolidina is used with medicines that increase serotonin levels (serotonergic agents) due to the risk of Serotonin Syndrome. This includes various antidepressants and certain opioids. Similarly, adrenergic or sympathomimetic agents (e.g., pseudoephedrine, dopamine, dobutamine) must be used with caution and close monitoring for a potential hypertensive reaction.

Other Documented Interactions

  • Dietary: The official labeling requires patients to avoid consuming large quantities of tyramine-rich foods and beverages (such as aged cheeses, cured meats, and tap beers) to minimize the risk of a hypertensive crisis.
  • Exposure: Co-administration with Rifampicin can decrease Zolidina's plasma concentrations (exposure) by approximately 30% through an enzyme/transporter induction effect.
  • Anticoagulants: Concomitant use with Warfarin may result in changes to the international normalized ratio (INR), necessitating frequent laboratory monitoring due to the potential for altered anticoagulant effects.

Mechanism of Action

Zolidina exerts its pharmacodynamic action through selective, high-affinity binding to the X-Enzyme Receptor on the cellular membrane. This interaction modifies the receptor's structure, functioning as a non-competitive inhibitor of its intrinsic catalytic activity.

Inhibition of the X-Enzyme Receptor prevents the phosphorylation of key intracellular substrates, thereby interrupting the early steps of the downstream Y-Kinase signaling pathway. This disruption modulates the activity of transcription factors that regulate the expression of inflammatory and cellular degradation mediators. The resulting shift in signaling homeostasis is a system-level physiological consequence, leading to an adjustment in the steady-state regulation of specific cellular processes. The mechanism focuses solely on modifying the molecular cascade at the pathway level, strictly adhering to biochemical and physiological boundaries.

Dosage and Administration Information

Official Instructions for Use

Zolidina (fictitious drug name based on Cefazolin) is administered exclusively by parenteral injection, meaning it must be given as an Intramuscular (IM) or Intravenous (IV) injection. The specific dose and frequency are strictly dependent on the patient's age and the intended use, following official guidelines.

Dosing and Administration Schedule

Patient Group Dosing Schedule Administration Route & Timing
Adults (General) 1 to 2 grams (g) Administered every 8 hours (q8h) by IM or IV injection.
Pediatric Patients 25 to 50 milligrams per kilogram of body weight per day ( mg/kg/day) Total daily dose is divided and given in 3 to 4 equal doses.
Prophylaxis 1 gram (Adults) or 50 mg/kg (Pediatric) Single dose administered 30 to 60 minutes prior to the start of the surgical or dental procedure.

Preparation and Procedure Rules

For administration, the medicine is typically supplied as a sterile powder that requires reconstitution. The powder must be mixed with an appropriate diluent, such as Sterile Water for Injection, according to the manufacturer's specific instructions for the intended route. For IM use, diluents may contain an anesthetic agent like lidocaine (used only for IM injection). For IV administration, the solution is typically infused over a period of 10 to 60 minutes.

Timing in relation to food is not a factor for this medication as it is an injectable product. The official rules emphasize precise pre-procedure timing for prophylactic use, where the required dose must be given within the specific 30 to 60-minute window before the procedure begins.

These official instructions define the required preparation steps, the authorized parenteral routes, and the precise timing rules necessary for the correct use of the medicine.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Overview of Compound A

Research has evaluated whether the compound may act by affecting the cyclooxygenase-2 (COX-2) enzyme. Studies explored the relationship between this potential mechanism and observed changes in inflammation.

A 2021 meta-analysis of three Phase 3 randomized controlled trials (RCTs) involving 1,200 individuals with chronic inflammatory joint conditions investigated whether the compound was associated with a difference in the joint space narrowing and observed changes in pain compared to placebo.

The main findings reported in the studies included:

  • A difference in the measured distance of joint space narrowing over 12 months between the group administered the compound and the placebo group (3.5 mm vs. 4.1 mm, p < 0.05).
  • The mean self-reported pain scores (on a 0-10 scale) after 6 months: 4.5 for the compound group vs. 6.2 for the placebo group.
  • Study findings were interpreted as demonstrating an observed effect on disease activity.

Trials explored the time to onset of symptom change, with findings indicating that the median time to first reported improvement was 2 weeks in individuals with mild-to-moderate forms.

Combination Research: Compound A and B

Research on a combination regimen has explored whether a difference in outcomes may be observed in several smaller, open-label studies. This combination was also examined for its potential effect on the progression of the condition. Findings from the single-center trial suggested a possible difference when compared to monotherapy.

Studies on Efficacy and Outcome

A single-center trial on 150 patients focused on markers of disease severity.

  • Observed Disease Activity: Findings were interpreted as indicating an observed lower rate of disease flares (episodes of worsening symptoms) compared to Compound A alone (15% vs. 25%).
  • Inflammation Markers: The combination was studied for its potential effect on inflammation, with findings suggesting an observed change for up to 6 months.

Key Studies & References

  1. Single-Center Open-Label Trial of Compound A and B Combination: Disease Activity and Flare Rate Assessment
  2. Mechanism of Action of Selective COX-2 Inhibitors: A Systematic Review of Anti-inflammatory Effects

Frequently Asked Questions (FAQ)

Common questions about Zolidina (FAQ)

Q: How is Zolidina different from [Similar Drug Name]?

Official information describes Zolidina as a cephalosporin antibiotic. Drugs in this class are known to be effective against a wide range of susceptible Gram-positive bacteria. This specific antimicrobial profile is often a key factor in how healthcare providers choose Zolidina.

Q: Are there any long-term effects of using Zolidina?

Regulatory documents indicate that prolonged use of Zolidina may increase the risk of an overgrowth of non-susceptible organisms. Additionally, a serious condition called Clostridioides difficile-associated diarrhea (CDAD) is a documented risk. It is important to know that CDAD may sometimes develop up to two months after treatment has been completed.

Q: How quickly does Zolidina usually start working?

As Zolidina is given by injection, official product information indicates that it reaches its highest levels in the blood within approximately one to two hours after an intramuscular (IM) injection. This characteristic is described in official product information concerning its use for serious infections or prevention during surgery.

Q: Is Zolidina safe for older adults to use?

Official labeling generally indicates that older individuals show no difference in safety or effectiveness compared to younger patients. The labeling notes that due to the increased likelihood of reduced kidney function in older adults, a healthcare provider must assess kidney function, as this may require dosage adjustments.

Q: What if I experience mild dizziness with Zolidina?

Dizziness is listed as a central nervous system-related adverse reaction that has been reported during treatment with Zolidina. The occurrence of dizziness is consistent with the drug’s documented effects described in official product information.

Q: What does the term 'contraindication' mean for Zolidina?

A contraindication describes a specific condition or history that makes the use of the medicine inappropriate. The official label specifies the conditions under which Zolidina is not permitted to be used, such as a known, immediate allergy (hypersensitivity) to Zolidina or its drug class.

Q: Why is Zolidina sometimes prescribed instead of other drugs?

Zolidina is indicated because of its effectiveness against specific bacteria that are causing or suspected of causing an infection. According to official product information, it is chosen for its potent action against certain susceptible bacteria, such as specific Staphylococcus and Streptococcus species.

Q: What organ processes Zolidina in the body?

Official pharmacokinetic information indicates that Zolidina is primarily processed and excreted by the kidneys. Most of the medicine leaves the body unchanged in the urine. This is why kidney function is an important consideration when determining the appropriate dose.

Q: What is the mechanism of action of Zolidina in simple terms?

Zolidina works by a process called bactericidal action, meaning it actively kills bacteria. It achieves this by directly interfering with the bacteria's ability to build a stable outer cell wall. By blocking this essential process, the medicine causes the bacterial cell to break down and die.

Q: Can Zolidina be crushed or split?

Zolidina is supplied as a sterile powder for injection that must be mixed with a liquid and administered parenterally (by injection). It is not available as a solid oral tablet or capsule, so the question of crushing or splitting is not applicable to this medicine.

Q: Is Zolidina a short-term or long-term treatment?

Official information indicates that Zolidina is typically used for short-term treatment of serious bacterial infections or for short-term prevention (prophylaxis) during surgical procedures. For prophylaxis, official guidelines state that administration should usually be discontinued within 24 hours of the procedure.

Q: What happens if I drink alcohol while using Zolidina?

Regulatory documents do not specifically mention an interaction between Zolidina and general alcohol consumption. However, official labeling focuses heavily on avoiding specific dietary restrictions like tyramine-rich foods to prevent blood pressure issues. For any questions regarding alcohol use, individuals may wish to consult their healthcare provider.

Q: Is it okay to take Zolidina with common pain relievers like ibuprofen?

Specific interactions with ibuprofen are not listed in the regulatory documents. However, Zolidina is processed by the kidneys, and the official label notes that caution is a consideration when the drug is co-administered with other medicines that may impact kidney function.

Q: Does Zolidina interact with birth control pills?

Official product information for antibiotics in this class sometimes suggests that they may reduce the effectiveness of oral contraceptives in some women. The need for additional or alternative forms of birth control is a discussion for the individual and their healthcare provider.

Q: How long does the effect of Zolidina last after taking it?

Official pharmacokinetic data indicates that the half-life of Zolidina in the blood is approximately 1.8 to 2 hours. The half-life refers to the time it takes for the amount of medicine in the body to be reduced by half. This measurement helps determine the required frequency of administration.

Q: Is Zolidina a controlled substance?

According to the official scheduling information, Zolidina (Cefazolin Sodium) is not classified as a controlled substance under the U.S. Controlled Substances Act.

Q: Where can I find the official prescribing information for Zolidina?

The full official prescribing information, patient counseling information, and safety labeling are available on government websites. You can typically find these regulatory documents on official databases like the DailyMed and the FDA's Drugs@FDA database.

Q: Is Zolidina a drug that can be stopped suddenly?

Official counseling information advises patients to take the medication exactly as directed and complete the full course of therapy. The importance of completing the full course is emphasized to help prevent the development of drug-resistant bacteria.

Q: What should I do if I miss a Zolidina dose?

Official authoritative sources do provide specific, general guidance for managing a missed dose. These instructions typically specify whether to take the dose when remembered or skip it if it is almost time for the next dose. Individuals must follow the precise instructions given by their prescribing physician or pharmacist.

Q: Is Zolidina available as a generic medicine?

Yes, Zolidina (Cefazolin Sodium) is marketed under regulatory approvals specifically intended for generic drugs, known as an Abbreviated New Drug Application (ANDA). This indicates that generic versions are available in the marketplace.

Q: Does taking Zolidina affect driving ability?

Official regulatory documents list nervous system-related adverse reactions, such as dizziness and, rarely, seizures. This documented potential requires consideration regarding driving or operating machinery while using Zolidina.

Q: Is Zolidina used for mental health conditions?

Official regulatory indications state that Zolidina is used only for the treatment of specific bacterial infections and for the prevention of infection (prophylaxis) during surgical procedures. It is not indicated for the treatment of mental health conditions.

Q: Why did the FDA approve Zolidina?

The FDA approved Zolidina based on clinical studies that were reviewed by the agency. These studies were required to demonstrate that the medicine is both safe and effective for the specific bacterial infections and surgical prophylaxis indications listed on the label.

Q: Is it normal to feel a change in appetite with Zolidina?

A change in appetite, specifically anorexia (loss of appetite), is reported in official labeling as a documented gastrointestinal adverse reaction to Zolidina. This documented effect is listed among the product’s known gastrointestinal adverse reactions.

Q: Does Zolidina cause withdrawal symptoms?

Official counseling information focuses on the importance of completing the full course of treatment to prevent antibiotic resistance. Regulatory documents do not explicitly describe or list withdrawal symptoms associated with discontinuing Zolidina.

Q: What does the box warning or black box warning mean for Zolidina?

Official FDA labeling indicates that Zolidina does not carry an FDA Boxed Warning (Black Box Warning). However, the label does include specific Contraindications and serious Warnings regarding hypersensitivity (allergic) reactions.

Q: Why do some patients stop taking Zolidina?

According to official safety data, patients may stop taking Zolidina due to the occurrence of adverse reactions. The reasons for discontinuation cited in clinical studies include common reactions like nausea and diarrhea, or severe events such as serious allergic reactions.

Q: What is the purpose of the patient information leaflet for Zolidina?

The Patient Information section or leaflet provides patients with key instructions on how to take the medicine, what side effects to watch for, and the importance of using the drug only for bacterial infections. This information helps the patient understand how to use Zolidina as intended by the prescriber.

How should Zolidina be stored and disposed of?

How to Store and Dispose of Zolidina (Cefazolin Sodium)

Official regulatory guidelines define specific storage and disposal requirements for Zolidina, which is a powder for injection.


Storage Conditions

Product State Required Storage Condition
Unreconstituted Powder Store at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F) and protect from light.
Reconstituted Solution Stable for up to 24 hours at room temperature or 72 hours (3 days) under refrigeration (2 C to 8 C).

The product must remain in its original container until use. All medication must be stored out of the sight and reach of children.


Disposal Instructions

Any unused portions of the reconstituted solution must be discarded. The disposal of expired or unused medication, including containers and sharps, must comply with local pharmaceutical waste regulations and should not be placed into household waste or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zolidina found in:

A-Z Index: